https://www.fool.com/investing/general/2013/11/09/is-this-cubists-biggest-opportunity.aspx
https://www.fool.com/investing/general/2013/09/12/the-neulasta-question.aspx
https://www.fool.com/investing/general/2013/09/11/next-leaders-in-technology-and-health-care.aspx
https://www.fool.com/investing/general/2013/11/29/is-there-more-to-isis-pharmaceuticals-than-kynamro.aspx
https://www.fool.com/investing/general/2014/04/04/the-battle-of-the-cruise-liners.aspx
https://www.fool.com/investing/high-growth/2013/10/15/the-fight-for-the-hypercholesterolemia-market.aspx
https://www.fool.com/investing/general/2013/09/09/the-treatment-of-rare-diseases-offers-unique-oppor.aspx
https://www.fool.com/investing/general/2013/10/07/array-biopharma-needs-a-partner-to-take-it-to-the.aspx
https://www.fool.com/investing/general/2013/09/20/investing-in-counteracting-biological-and-chemical.aspx
https://www.fool.com/investing/general/2013/09/10/tackling-pain-and-addiction.aspx
https://www.fool.com/investing/general/2013/12/09/treating-parkinsons-disease-psychosis.aspx
https://www.fool.com/investing/general/2013/11/22/opportunities-in-lung-cancer-therapies.aspx
https://www.fool.com/investing/general/2013/08/29/profiting-from-farming.aspx
https://www.fool.com/investing/general/2014/03/28/does-this-stock-warrant-a-9-billion-market-cap.aspx
https://www.fool.com/investing/general/2013/09/27/a-reshuffle-in-a-27-billion-market.aspx
